Clinical Trials
49 trialsKRDI in Transplant-Eligible MM
Massachusetts General Hospital
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
IsaIberVD
Dana-Farber Cancer Institute
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
CM336-RI
Institute of Hematology & Blood Diseases Hospital, China
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
ICING
Samsung Medical Center
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
IMPEDE
Medical College of Wisconsin
BOREALIS
Canadian Myeloma Research Group
EMAT
Medical College of Wisconsin
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
HEME-18
University of Illinois at Chicago
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
GRAALL-2024
Assistance Publique - HĂ´pitaux de Paris
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
VICD
Medical College of Wisconsin
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
ISABELA
Massachusetts General Hospital
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
UltraFrailMM
University of Utah
MODIFY
University College, London
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Columbia University
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
REST
Oslo University Hospital
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
Canadian Myeloma Research Group
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
University of Virginia
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Washington University School of Medicine
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Washington University School of Medicine
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Karolinska Institutet
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Poitiers University Hospital
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
University of California, San Francisco
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
ICE
Assistance Publique - HĂ´pitaux de Paris